Risteys ·

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution	Test outcome NA N A AA L LL H HH
3032700	s-goodpk	— (—)	488	564	100.00%	Distribution not available
3032700	s-goodpk	u/ml (u/ml)	27	174	0.00%

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

All kidney diseases

288

160

12.35

232.62

1.7

1.0

64.18

1.82

u/ml

—

Renal tubulo-interstitial diseases

276

176

11.73

228.56

1.7

1.1

67.33

64.98

u/ml

—

Condition for Implicit Sepsis (Organ dysfunction codes)

230

189

8.62

151.81

1.8

1.2

70.58

59.63

u/ml

—

Implicit Sepsis

227

195

8.54

151.67

1.8

1.2

65.99

59.63

u/ml

—

Implicit Sepsis

217

191

8.60

148.21

1.8

1.1

65.99

9.00

u/ml

—

Condition for Implicit Sepsis (Organ dysfunction codes)

221

188

8.13

138.12

1.7

1.2

47.55

59.63

u/ml

—

Heart failure, not strict

189

174

7.40

109.19

1.4

1.6

8.26

95.09

u/ml

—

ILD medications: immunosuppressive drugs

143

192

6.94

90.74

2.5

1.0

74.92

6.08

u/ml

—

Extracorporeal dialysis

32.43

88.12

3.2

1.0

116.95

—

u/ml

—

Other necrotizing vasculopathies

22.55

87.26

4.4

1.0

103.73

—

u/ml

—

All pneumoniae

204

267

5.12

83.75

1.6

1.4

58.40

56.76

u/ml

—

Pneumonias (Asthma/COPD co-morbidities)

201

270

5.01

80.85

1.6

1.4

58.40

56.76

u/ml

—

ILD medications: prednisolone, methylprednisolone, prednisone

203

214

5.32

79.90

1.9

1.0

39.95

4.76

u/ml

—

Influenza and pneumonia

204

262

4.96

79.36

1.6

1.4

52.73

60.43

u/ml

—

ILD medications

209

219

5.18

79.06

1.8

1.0

37.21

4.76

u/ml

—

Pneumonia, organism unspecified

183

247

5.20

78.09

1.6

1.5

58.49

64.68

u/ml

—

COPD/asthma/ILD related pneumonia or pneumonia derived septicaemia

182

203

5.44

76.08

1.6

1.3

58.40

88.67

u/ml

—

182

203

5.44

76.08

1.6

1.3

58.40

88.67

u/ml

—

Pneumonia (excl. viral and due to other infectious organisms not elsewhere classified)

195

277

4.81

75.61

1.6

1.4

65.58

53.48

u/ml

—

Bacterial infection, other or unspecified

127

174

6.35

72.25

1.2

1.5

66.88

14.86

u/ml

—

Other necrotizing vasculopathies (FG)

24.78

72.05

3.0

1.0

11.30

—

u/ml

—

Kidney transplant status

35.37

71.24

3.5

1.0

79.37

—

u/ml

—

Other bacterial diseases

183

256

4.82

70.65

1.2

1.5

70.14

76.55

u/ml

—

L04AD Calcineurin inhibitors

16.30

68.45

3.0

1.0

70.06

—

u/ml

—

Bacterial infection, other or unspecified

130

188

5.86

67.73

1.2

1.6

59.59

63.67

u/ml

—

Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

186

287

4.48

66.85

1.2

1.6

4.08

77.59

u/ml

—

First line medication for Crohn's disease

190

221

4.65

64.34

1.6

1.1

7.43

50.37

u/ml

—

Other bacterial diseases

183

260

4.47

63.57

1.2

1.7

69.69

60.81

u/ml

—

Fever of other and unknown origin

122

191

5.70

63.10

1.7

1.4

79.21

6.13

u/ml

—

Transplanted organ and tissue status

16.97

62.58

3.4

1.0

72.45

—

u/ml

—

Explicit Sepsis

136

6.47

56.18

1.4

1.1

103.14

10.46

u/ml

—

Septicaemia

146

5.98

51.49

1.4

1.6

103.14

14.86

u/ml

—

Oral corticosteroids

174

267

3.87

49.46

1.5

1.2

43.61

52.89

u/ml

—

Acute tubulo-interstitial nephritis

136

5.72

46.27

1.4

1.1

88.48

77.00

u/ml

—

Dyspnoea

154

305

3.74

45.24

1.4

162.86

7.07

u/ml

—

Inflammatory bowel disease treatment related agents

176

279

3.53

43.32

1.7

1.3

41.02

49.72

u/ml

0.06

ILD medications: azathioprine

11.41

40.44

4.2

1.0

71.07

—

u/ml

—

Erysipelas

112

218

3.93

35.72

1.0

1.6

2.58

76.55

u/ml

—

Azathioprine

8.98

34.18

4.2

1.0

71.07

—

u/ml

—

Autoimmune diseases related-to ILD

127

326

3.34

33.18

2.7

1.0

103.73

6.70

u/ml

1.15

Abnormalities of breathing

125

204

3.56

31.76

1.2

1.4

180.80

9.33

u/ml

—

Persons encountering health services for specific procedures and health care

154

310

2.98

30.20

2.0

1.1

65.62

30.00

u/ml

—

Autoimmune diseases excluding thyroid diseases

152

277

3.00

29.15

1.9

1.0

47.62

6.83

u/ml

—

Autoimmune diseases excluding thyroid diseases, strict definition

149

275

2.97

28.20

1.9

1.0

47.62

6.83

u/ml

—

Bacterial pneumonia (organism specified)

192

3.93

28.05

1.7

1.4

99.64

13.13

u/ml

—

Reimbursement for rheumatic diseases

247

3.64

27.98

2.8

1.1

95.33

61.81

u/ml

—

Hypertensive diseases

102

158

3.65

26.56

1.4

1.3

9.98

44.89

u/ml

—

Hypertension

102

158

3.65

26.55

1.4

1.3

9.98

44.89

u/ml

—

COPD/asthma/ILD related infections

128

203

3.16

25.93

1.4

1.3

3.38

88.67

u/ml

—

COPD/asthma related infections

128

203

3.16

25.93

1.4

1.3

3.38

88.67

u/ml

—

Dental caries

115

4.78

25.16

1.9

1.5

9.08

92.06

u/ml

—

Any death

100

214

3.35

25.09

1.0

1.5

—

43.22

—

L04AX Other immunosuppressants

259

3.29

22.74

2.6

1.2

61.61

87.57

u/ml

—

Diseases of arteries, arterioles and capillaries

102

248

3.04

22.21

1.6

1.2

61.61

9.24

u/ml

—

Asthma, excluding more controls

109

3.83

21.60

1.3

1.4

82.20

75.72

u/ml

—

Second line medication for Crohn's disease

270

3.15

21.28

2.6

1.2

61.61

87.57

u/ml

—

Tramadol

105

217

2.98

20.87

1.6

1.4

103.80

34.31

u/ml

—

Symptoms and signs involving the circulatory and respiratory systems

116

204

2.85

20.04

1.3

1.4

2.40

9.33

u/ml

—

Autoimmune diseases

139

277

2.55

19.78

2.2

1.0

10.48

6.83

u/ml

—

Certain infectious and parasitic diseases

110

189

2.92

19.75

1.8

1.6

8.73

51.70

u/ml

—

Diabetes, varying definitions

127

286

2.61

19.65

1.3

1.5

102.30

49.82

u/ml

—

Diabetes mellitus

126

287

2.57

18.97

1.3

1.5

102.30

49.82

u/ml

—

Asthma

131

3.28

18.07

1.3

82.20

75.72

u/ml

—

Asthma (only as main-diagnosis), excluding more controls

109

3.52

16.85

1.1

1.4

77.08

75.72

u/ml

—

Asthma (mode)

133

3.18

16.78

1.3

82.20

75.72

u/ml

—

Examination and observation for other reasons

182

2.86

16.56

1.0

1.7

—

48.50

—

Pain in throat and chest

198

2.79

16.39

1.3

1.4

11.15

9.33

u/ml

—

Asthma (only as main-diagnosis)

131

3.10

14.69

1.1

1.3

77.08

75.72

u/ml

—

Diabetes medication

121

312

2.30

14.68

1.3

1.5

102.30

49.82

u/ml

—

Polyarthropathies

225

2.62

14.62

1.0

1.4

—

60.45

—

Complications of surgical and medical care, not elsewhere classified

117

354

2.26

14.23

1.7

1.3

68.75

53.76

u/ml

—

Dipeptidyl peptidase 4 (DPP-4) inhibitors

232

2.70

14.18

1.5

102.30

45.15

u/ml

—

Used for control exclusion in common control thyroid runs

119

265

2.27

13.41

1.6

1.0

11.06

6.83

u/ml

—

Diabetes, insuline treatment (Kela reimbursement), excluding more controls

106

276

2.32

13.15

1.2

1.5

6.50

49.82

u/ml

—

Complications of procedures, not elsewhere classified

347

2.32

13.00

1.3

101.74

53.76

u/ml

—

Statin medication

141

2.83

12.81

1.1

1.2

1.52

58.14

u/ml

—

Opioids

108

244

2.30

12.68

1.6

1.5

7.06

32.39

u/ml

—

Disorders of lipoprotein metabolism and other lipidaemias

236

2.36

11.82

1.0

1.6

—

62.96

—

Persons with potential health hazards related to family and personal history and certain conditions influencing health status

109

331

2.15

11.61

2.1

1.3

79.33

53.28

u/ml

—

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (FINNGEN)

3.69

10.73

1.1

—

77.06

—

Abnormal findings on examination of blood, without diagnosis

244

2.49

10.65

1.6

1.4

71.57

10.06

u/ml

—

Diseases of the skin and subcutaneous tissue

110

262

2.11

10.50

1.5

1.4

9.04

60.59

u/ml

—

Diarrhoea and gastroenteritis of presumed infectious origin

330

2.24

10.46

1.8

1.4

83.63

32.94

u/ml

—

Cardiomyopathy, other and unspecified

12.06

10.33

1.0

—

Diabetes, insulin treatment (Kela reimbursement)

110

328

2.03

10.02

1.2

1.5

6.50

72.46

u/ml

—

Diarrhoea and gastroenteritis of presumed infectious origin

108

366

1.95

9.03

1.6

1.4

56.23

54.63

u/ml

—

116

314

1.91

8.67

1.7

1.4

5.11

91.86

u/ml

—

Myocardial infarction

167

2.45

8.59

1.1

1.8

—

44.78

—

Codeine or tramadol medication

117

345

1.86

8.19

1.4

8.34

68.47

u/ml

—

Intestinal infectious diseases

395

1.90

8.04

1.7

1.4

83.63

46.65

u/ml

—

Mycoses

129

2.80

7.56

1.0

1.4

—

8.92

—

Pure hypercholesterolaemia

224

2.10

7.44

1.0

1.6

—

48.05

—

Liquid cancers, helper endpoint

180

2.38

7.24

1.0

1.4

—

53.85

—

Hyperlipidaemia, other/unspecified

164

2.47

7.16

1.0

1.6

—

13.87

—

Other diseases of urinary system

100

305

1.84

6.98

1.4

1.5

14.44

76.16

u/ml

—

Myocardial infarction, strict

159

2.29

6.64

1.1

1.8

—

12.26

—

Intestinal infectious diseases

112

369

1.73

6.47

1.6

1.4

56.23

51.69

u/ml

—

Complications of cardiac and vascular prosthetic devices, implants and grafts

15.15

5.91

1.0

—

Chronic lower respiratory diseases

115

365

1.68

5.86

1.3

1.5

69.32

50.97

u/ml

—

Bronchitis

104

384

1.71

5.85

1.9

1.3

4.08

77.00

u/ml

—

Periodontitis

360

1.73

5.56

1.6

1.3

104.94

49.14

u/ml

—

Chronic periodontitis, including avohilmo

361

1.71

5.31

1.6

1.3

104.94

49.14

u/ml

—

Mycoses

414

1.72

5.13

1.3

1.5

105.38

44.24

u/ml

—

Myocardial infarction, without ST-elevation

196

2.09

5.09

1.0

1.5

—

10.85

—

Symptoms and signs involving the urinary system

322

1.78

5.08

1.6

1.4

8.76

57.95

u/ml

—

COPD, hospital admissions 3, with asthma pneumonia sepsis

130

2.30

4.92

1.0

1.2

—

11.79

—

Gingivitis and periodontal diseases

293

1.67

4.84

1.5

1.2

6.69

48.97

u/ml

—

Unspecified nephritic syndrome

11.52

4.79

1.0

—

COPD related to multimorbidity

182

2.04

4.64

1.0

1.6

—

10.85

—

Persons encountering health services for specific procedures, not carried out

4.83

4.49

1.0

—

Gastroduodenal ulcer

129

2.32

4.45

1.1

1.2

—

15.92

—

Anxiety (asthma-related co-morbidities)

217

1.89

4.43

1.1

1.5

—

33.04

—

Drugs, medicaments and biological substances causing adverse effects in therapeutic use

4.25

4.31

1.1

1.0

—

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified

343

1.62

4.21

1.9

1.3

9.62

75.14

u/ml

—

Nerve, nerve root and plexus disorders

367

1.59

4.15

1.3

1.4

154.93

26.70

u/ml

—

Asthma, hospital admissions , main diagnosis only

393

1.66

4.14

1.1

1.6

77.08

52.23

u/ml

—

Primary_lymphoid and hematopoietic malignant neoplasms

123

2.28

4.02

1.0

1.4

—

13.72

—

Pericarditis

10.04

4.01

1.0

—

Elevated blood glucose level

4.46

3.93

1.0

—

Obesity due to excess calories

219

1.92

3.89

1.1

1.3

—

60.80

—

Other obstructive and reflux uropathy

12.03

3.76

1.0

—

COPD, hospital admission 2, with asthma infections

153

2.02

3.75

1.0

1.4

—

11.94

—

Personality disorders, excluding more controls

2.37

3.63

1.0

1.2

—

6.46

—

All anxiety disorders

238

1.76

3.63

1.1

1.5

—

33.31

—

Anxiety disorders, excluding more controls

287

1.63

3.62

1.1

1.6

—

53.32

—

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

129

2.17

3.62

1.1

1.6

—

5.60

—

Glucagon-like peptide-1 (GLP-1) analogues

129

2.17

3.62

1.1

1.6

—

5.60

—

Anxiety disorders

345

1.56

3.26

1.1

1.5

—

69.50

—

Acute upper respiratory infections

373

1.50

3.24

1.9

1.3

5.11

76.77

u/ml

—

Attention to artificial openings

6.39

3.18

1.1

1.0

—

Neurotic, stress-related and somatoform disorders

344

1.55

3.15

1.1

1.5

—

69.50

—

Giant cell arteritis

4.46

2.79

1.0

—

Hypersensitivity pneumonitis due to organic dust

8.39

2.75

1.0

—

Pain (limb, back, neck, head abdominally)

202

1.56

2.62

1.1

1.5

—

35.02

—

Sicca syndrome [Sjögren]

3.34

2.60

1.1

1.0

—

Methotrexate

2.86

2.54

1.1

1.0

—

Later onset COPD

130

1.84

2.47

1.1

1.5

—

10.83

—

Asthma, including avohilmo

398

1.40

2.46

1.2

1.5

68.73

48.77

u/ml

—

Other postsurgical states

3.82

2.46

1.0

—

Temporal arteritis

5.02

2.40

1.0

—

Viral infections characterized by skin and mucous membrane lesions

418

1.45

2.35

1.2

1.5

5.97

69.99

u/ml

—

Myocardial infarction, with ST-elevation

2.09

2.32

1.1

1.2

—

11.50

—

Giant cell arteritis with polymyalgia rheumatica

4.63

2.27

1.0

1.1

—

Cardiodefibrillation

192

1.72

2.27

1.0

1.5

—

11.66

—

Mental and behavioural disorders due to opioids

5.57

2.21

1.0

—

Medical abortion

143

1.63

2.21

1.0

1.6

—

129.14

—

Budesonide

2.62

2.14

1.0

—

Diseases of pulp and periapical tissues, including avohilmo

320

1.39

2.12

1.6

1.5

3.90

35.06

u/ml

—

Psoriatic and enteropathic arthropathies

2.71

2.06

1.1

1.0

—

Coxarthrosis, primary, with hip surgery

236

1.59

2.06

1.0

1.5

—

49.50

—

Use of memantine

135

0.37

2.04

1.0

1.2

—

13.53

—

Use of other anti-dementia drugs

135

0.37

2.04

1.0

1.2

—

13.53

—

Other anxiety disorders

183

1.61

1.86

1.1

1.6

—

8.84

—

Alzheimer disease, including avohilmo

157

0.45

1.80

1.0

1.4

—

10.83

—

COPD, hospital admissions 1, only main diagnosis

165

1.61

1.71

1.0

1.6

—

11.83

—

Chronic rhinitis, nasopharyngitis and pharyngitis

151

1.66

1.59

1.0

1.4

—

7.65

—

Injuries to the hip and thigh

239

1.48

1.53

1.0

1.5

—

11.83

—

Rheumatoid arthritis

123

1.68

1.52

1.0

1.7

—

104.32

—

Hallux valgus (acquired)

104

1.66

1.47

1.0

1.4

—

117.66

—

Disorders of gallbladder, biliary tract and pancreas

364

1.32

1.46

1.4

101.58

45.16

u/ml

—

Epilepsy

155

1.61

1.44

1.1

1.3

—

8.23

—

Asthma and opportunity respiratory infection

3.13

1.44

1.0

1.1

—

Symptoms and signs involving speech and voice

164

1.59

1.42

1.0

1.3

—

10.19

—

Polyarthrosis

1.81

1.38

1.0

1.4

—

88.52

—

Alzheimer disease

145

0.50

1.35

1.0

1.4

—

13.46

—

Dorsopathies

328

1.29

1.33

1.6

1.5

8.52

54.44

u/ml

—

Papulosquamous disorders

192

1.51

1.31

1.1

1.3

—

14.16

—

Any mental disorder

329

1.28

1.29

1.0

1.5

—

44.33

—

Disorders of adult personality and behaviour

122

1.64

1.27

1.1

—

6.46

—

Malignant neoplasm of breast, ER-positive, including Hilmo

110

0.49

1.22

1.1

1.4

—

182.30

—

L02BG Aromatase inhibitors

130

0.46

1.15

1.2

1.6

—

181.28

—

Trigger finger

1.90

1.12

1.0

—

Malignant neoplasm of breast, HER-positive

110

0.50

1.11

1.1

1.4

—

182.30

—

Sleep disorders (combined)

363

1.24

1.10

1.1

1.6

9.52

72.06

u/ml

—

conjunctival haemorrhage

2.26

1.10

1.0

—

Unspecific neurodegenerative disorder

175

0.62

1.06

1.0

1.5

—

46.75

—

Medicines for HER+ breast cancer

143

0.53

1.03

1.1

1.5

—

129.87

—

General examination and investigation of persons without complaint and reported diagnosis

185

1.33

1.00

1.1

1.7

—

45.11

—

Pacemaker

173

1.44

0.98

1.1

1.6

—

10.85

—

Reactive arthropathies, FINNGEN

2.18

0.98

1.0

—

Spontaneous abortion

119

0.57

0.98

1.0

1.6

—

102.38

—

Other shoulder lesions

1.95

0.97

1.1

1.0

—

Use of hypnotics and sedatives

364

1.23

0.96

2.2

1.2

9.53

63.87

u/ml

—

Inflammatory diseases of female pelvic organs

176

1.38

0.95

1.1

1.5

—

117.49

—

Status post-ami

100

1.52

0.95

1.1

1.7

—

14.88

—

Pregnancy with abortive outcome

146

1.36

0.95

1.0

1.6

—

129.14

—

Degenerative diseases of the nervous system

155

0.62

0.94

1.1

1.4

—

10.83

—

Artrosis, including avohilmo

269

1.26

0.94

1.0

1.2

—

32.78

—

Alzheimer’s disease, strict definition

120

0.55

0.94

1.0

1.2

—

13.53

—

Dorsalgia

326

1.23

0.93

1.5

8.52

56.59

u/ml

—

Follow-up examination after treatment for conditions other than malignant neoplasms

143

1.39

0.90

1.1

1.6

—

63.63

—

Injury of muscle and tendon at shoulder and upper arm level

203

1.38

0.86

1.0

1.5

—

15.46

—

Redundant prepuce, phimosis and paraphimosis

127

1.48

0.84

1.1

1.4

—

10.60

—

Infectious mononucleosis

1.94

0.84

1.2

1.1

—

Benign neoplasm: Colon, unspecified

138

1.45

0.81

1.1

1.4

—

13.72

—

Arthrosis

212

1.27

0.81

1.0

1.4

—

60.45

—

Impotence

0.00

0.79

0.0

1.0

—

Dementia, including avohilmo

195

0.70

0.79

1.0

1.6

—

39.99

—

Inflammatory disorders of breast

0.00

0.79

0.0

1.0

—

Other functional intestinal disorders

202

1.33

0.74

1.0

1.8

—

45.55

—

Any dementia

161

0.69

0.72

1.0

1.4

—

10.83

—

Other intervertebral disc disorders

297

1.22

0.72

1.9

1.4

77.52

63.57

u/ml

—

Combinations of oral blood glucose lowering drugs

142

1.41

0.72

1.1

1.6

—

10.52

—

Rheumatoid arthritis, including avohilmo

185

1.35

0.71

1.0

1.3

—

14.13

—

Other benign neoplasms of skin

187

1.34

0.67

1.0

1.3

—

14.16

—

Fitting and adjustment of other devices

152

0.65

0.67

1.0

—

1.58

—

Dementia in Alzheimer disease

0.52

0.67

1.0

1.3

—

13.53

—

Fracture of femur

131

1.38

0.66

1.0

1.4

—

10.21

—

Organic, including symptomatic, mental disorders

215

1.26

0.65

1.0

1.6

—

39.99

—

Other disorders of penis

1.60

0.61

1.0

—

Prolapse and hernia of ovary and fallopian tube

0.00

0.60

0.0

1.1

—

Other dorsopathies, not elsewhere classified

327

1.17

0.59

1.5

8.52

54.44

u/ml

—

Infections with a predominantly sexual mode of transmission

114

1.40

0.58

1.2

1.1

—

6.46

—

Synovial cyst of popliteal space [Baker]

1.67

0.56

1.0

1.1

—

Unspecified mental disorder

211

1.28

0.56

1.0

1.3

—

6.11

—

Degeneration of macula and posterior pole

210

1.25

0.56

1.0

1.6

—

45.09

—

Alzheimer’s disease (Late onset)

106

0.63

0.55

1.0

1.2

—

13.53

—

Tonsillectomy and adenotomy

191

0.76

0.54

1.1

1.4

—

40.09

—

Dementia

181

0.76

0.54

1.0

1.7

—

39.99

—

Plantar fascial fibromatosis

1.58

0.54

1.0

—

Basal cell carcinoma, including avohilmo

188

0.77

0.52

1.1

1.4

—

101.20

—

Benign paroxysmal vertigo

145

0.69

0.50

1.0

1.4

—

13.72

—

Schizophrenia or delusion, excluding more controls

143

1.32

0.49

1.0

1.6

—

5.73

—

Poisoning by drugs, medicaments and biological substances

101

1.39

0.49

1.1

1.2

—

6.72

—

Spondylopathies (FG)

1.46

0.46

1.0

—

Necrosis of pulp, including avohilmo

300

1.20

0.45

1.3

1.4

—

38.22

—

Polycystic ovarian syndrome, consortium definition

177

1.20

0.45

1.0

1.5

—

117.49

—

Myocardial infarction, unclassifiable

113

0.71

0.43

1.0

1.2

—

11.79

—

Excessive vomiting in pregnancy

1.61

0.43

1.0

—

Gestational [pregnancy-induced] oedema and proteinuria without hypertension

1.61

0.43

1.0

—

Irregular menses

138

1.26

0.42

1.0

1.5

—

102.33

—

Any dementia, excluding more controls

143

0.77

0.42

1.0

1.4

—

9.19

—

Other benign neoplasm of uterus: Other parts/unspecified

0.00

0.41

0.0

1.1

—

Female infertility, tubal origin

0.00

0.41

0.0

1.0

—

Infections of breast associated with childbirth

0.00

0.41

0.0

1.0

—

Family history of certain disabilities and chronic diseases leading to disablement

0.00

0.41

0.0

1.0

—

Specific development disorders of scholastic skills

0.00

0.41

0.0

1.0

—

Haemorrhoids and perianal venous thrombosis

149

1.27

0.41

1.1

1.6

—

15.32

—

Nontraumatic intracranial haemmorrhage

105

1.33

0.41

1.1

1.2

—

9.75

—

Complications of the puerperium, not elsewhere classified

0.00

0.40

0.0

1.0

—

Labour and delivery complicated by intrapartum haemorrhage, not elsewhere classified

0.00

0.40

0.0

1.0

—

Injuries to the abdomen, lower back, lumbar spine and pelvis

211

1.22

0.40

1.0

1.3

—

9.14

—

Erosion and ectropion of cervix uteri

0.00

0.40

0.0

1.1

—

Suicide or other Intentional self-harm

105

0.67

0.39

1.1

1.2

—

6.72

—

Malignant neoplasm of skin

199

0.83

0.36

1.1

1.4

—

101.20

—

Localized swelling, mass and lump of skin and subcutaneous tissue

163

1.23

0.34

1.0

1.3

—

10.19

—

Diseases of external ear

182

1.21

0.33

1.0

1.3

—

13.72

—

Schizophrenia or delusion

155

1.23

0.32

1.0

1.3

—

7.86

—

Schizophrenia, schizotypal and delusional disorders

155

1.23

0.32

1.0

1.3

—

7.86

—

Seborrhoeic keratosis

110

1.27

0.31

1.0

1.5

—

13.72

—

Acute appendicitis, no complications

303

1.15

0.31

1.0

1.3

—

42.54

—

Fracture of rib(s), sternum and thoracic spine

164

0.79

0.30

1.1

—

11.50

—

Primary coxarthrosis, bilateral

148

1.22

0.29

1.0

1.4

—

13.72

—

Abrasion of teeth

148

1.22

0.29

1.0

1.4

—

7.50

—

Other malignant neoplasms of skin (=non-melanoma skin cancer)

186

0.85

0.29

1.1

1.5

—

101.20

—

145

1.20

0.28

1.0

1.4

—

11.95

—

Basal cell carcinoma

180

0.85

0.28

1.1

1.4

—

53.85

—

Disorders of tooth development and eruption

1.25

0.27

1.0

1.1

—

Infections with a predominantly sexual mode of transmission

156

1.19

0.27

1.2

1.4

—

7.34

—

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperium or nerve system disorders

121

0.74

0.27

1.1

—

5.77

—

Kela-code for severe mental illness

187

1.18

0.26

1.0

1.3

—

6.11

—

Atopic dermatitis, strict definition with reimbursement

118

1.23

0.26

1.1

1.6

—

9.33

—

Other reaction to severe stress, and adjustment disorders

152

1.18

0.23

1.1

1.4

—

60.76

—

Distal bite

0.00

0.21

0.0

1.1

—

Other assisted single delivery

0.00

0.21

0.0

1.0

—

Other and unspecified disease of Bartholin gland

0.00

0.21

0.0

1.0

—

Moderate visual impairment, binocular

0.00

0.21

0.0

1.1

—

Hypoparathyroidism

0.00

0.21

0.0

1.0

—

Muscle strain

0.00

0.21

0.0

1.0

—

Right bundle-branch block

0.00

0.21

0.0

1.0

—

Asthma mixed form (mode)

0.00

0.21

0.0

1.0

—

Other disorders of male genital organs

0.00

0.21

0.0

1.0

—

Premature separation of placenta [abruptio placentae]

0.00

0.20

0.0

1.0

—

Puerperal sepsis

1.25

0.20

1.0

—

Any mental disorder, or suicide (or attempt), or psychic disorders complicating pregnancy, partum or puerperum or nerve system disorders, excluding more controls

113

0.79

0.20

1.1

1.2

—

5.77

—

Embedded and impacted teeth

1.21

0.19

1.0

1.8

—

9.33

—

Use of anticholinesterases

155

0.86

0.19

1.0

1.5

—

46.75

—

N06DA Anticholinesterases

155

0.86

0.19

1.0

1.5

—

46.75

—

Benign mammary dysplasia

1.19

0.18

1.1

1.0

—

Dislocation, sprain and strain of joints and ligaments at ankle and foot level

173

0.86

0.17

1.0

1.6

—

8.04

—

Obstructed labour due to malposition and malpresentation of fetus

0.75

0.17

1.0

1.1

—

76.94

—

Malignant neoplasm of digestive organs

178

0.89

0.16

1.1

1.4

—

53.85

—

Long labour

1.15

0.15

1.0

1.1

—

76.94

—

Alzheimer disease, excluding more controls

0.77

0.14

1.0

2.5

—

11.06

—

Fissure and fistula of anal and rectal regions

112

1.16

0.14

1.0

1.5

—

11.60

—

Atopic dermatitis, strict definition

120

1.14

0.13

1.1

1.6

—

9.35

—

Other hearing loss

148

1.12

0.13

1.1

1.4

—

11.90

—

Acute appendicitis

368

1.07

0.12

1.0

1.5

—

53.50

—

Deviated nasal septum

199

0.90

0.11

1.0

1.6

—

11.86

—

Macular pucker

1.15

0.10

1.0

1.6

—

13.72

—

Other degenerative diseases of the nervous system

109

0.89

0.10

1.1

2.1

—

56.29

—

Viral and other specified intestinal infections

1.13

0.08

1.1

1.6

—

9.55

—

Striking against or struck by other objects

185

0.92

0.08

1.5

1.3

—

7.45

—

Persons encountering health services in other circumstances

214

0.93

0.07

1.1

1.3

—

13.89

—

Impacted teeth

1.04

0.07

1.0

1.9

—

11.00

—

Supplementary factors related to causes of morbidity and mortality classified elsewhere

162

0.93

0.06

1.1

1.4

—

10.17

—

Mouth breathing

232

0.95

0.05

1.0

1.4

—

8.17

—

Contraceptive management

126

0.95

0.03

1.1

1.3

—

148.55

—

Inflammatory bowel disease

162

1.05

0.02

1.1

1.2

—

7.56

—

Appendicitis, broad definition

381

1.02

0.02

1.0

1.5

—

50.92

—

Triptan medication for migraine, min. 3 purchases

180

0.97

0.00

1.0

1.5

—

86.33

—

Disease of hard tissues of teeth, NOS

159

1.02

0.00

1.0

1.4

—

76.95

—

117

0.96

0.00

1.0

1.5

—

13.72

—

severe traumatic brain injury, does not include concussion

115

1.04

0.00

1.0

1.1

—

11.50

—

Diseases of appendix

385

1.01

0.00

1.0

1.5

—

50.92

—

Acute suppurative otitis media

107

1.05

0.00

1.1

1.6

—

11.00

—

6-mercaptopurine

0.00

0.0

1.0

—

Tuberculosis of other organs

0.00

0.0

1.0

—

Wide developmental disorders

0.00

0.0

1.0

—

Injury of urinary and pelvic organs

0.00

0.0

1.0

—

Endometriosis of intestine

0.00

0.0

1.0

—

Endometriosis of fallopian tube

0.00

0.0

1.0

—

Malignant cancer of tonsil and base of tongue

0.00

-0.00

0.0

1.0

—

Crystal arthropathies, rheuma endpoint

0.00

-0.00

0.0

1.1

—

Juvenile rheumatoid arthirtis

0.00

-0.00

0.0

1.0

—

Benign neoplasm of other and unspecified sites

0.00

-0.00

0.0

1.0

—

Malignant neoplasm of oropharynx, including Hilmo

0.00

-0.00

0.0

1.0

—

Other and unspecified hydrocephalus

0.00

-0.00

0.0

1.0

—

Varus deformity, not elsewhere classified

0.00

-0.00

0.0

1.0

—

Epiphora

0.00

-0.00

0.0

1.0

—

Malignant neoplasm of other and unspecified female genital organs

0.00

-0.00

0.0

1.0

—

Myasthenia gravis

0.00

-0.00

0.0

1.0

—

Autoimmune thyroiditis

0.00

-0.00

0.0

1.0

—

Primary ovarian failure

0.00

-0.00

0.0

1.0

—

Malignant neoplasm of other and unspecified female genital organs, including Hilmo

0.00

-0.00

0.0

1.0

—

Burn and corrosion of shoulder and upper limb, except wrist and hand

0.00

-0.00

0.0

1.0

—

Malignant neoplasm of brain

0.00

-0.00

0.0

1.0

—

Mental and behabioural disorders of puerperum, not classified elsewhere, excluding more controls

0.00

-0.00

0.0

1.0

—

Procedures for purposes other than remedying health state

0.00

-0.00

0.0

1.0

—

0.00

-0.00

0.0

1.0

—

0.00

-0.00

0.0

1.2

—

Benign neoplasm: Lip

0.00

-0.00

0.0

1.0

—

Assault by unspecified means

0.00

-0.00

0.0

1.0

—

Autism spe, excluding more controls

0.00

-0.00

0.0

1.0

—

Exposure to other specified electric current

0.00

-0.00

0.0

1.0

—

Other maltreatment syndromes

0.00

-0.00

0.0

1.0

—

Mumps

0.00

-0.00

0.0

1.0

—

Other diseases of appendix

0.00

-0.00

0.0

1.0

—

Bursitis of shoulder

0.00

-0.00

0.0

1.0

—

Malignant cancer of tonsil and base of tongue, including Hilmo

0.00

-0.00

0.0

1.0

—

Vascular dementia (mixed)

0.00

-0.00

0.0

1.0

—

Juvenile osteochondrosis

0.00

-0.00

0.0

1.0

—

Hypertrichosis

0.00

-0.00

0.0

1.0

—

Inflammation of lacrimal passages (acute and unspecified)

0.00

-0.00

0.0

1.0

—

Acute otitis externa, noninfective

0.00

-0.00

0.0

1.0

—

Xanthelasma of eyelid

0.00

-0.00

0.0

1.0

—

Melanocytic naevi of upper limb, including shoulder

0.00

-0.00

0.0

1.0

—

Calcaneal spur

0.00

-0.00

0.0

1.0

—

conjunctival degenerations and deposits

0.00

-0.00

0.0

1.0

—

Vitamin B12 deficiency anemia due to intrinsic factor deficiency

0.00

-0.00

0.0

1.0

—

Hirsutism in women

0.00

-0.00

0.0

1.0

—

Pterygium

0.00

-0.00

0.0

1.0

—

Habit and impulse disorders

0.00

-0.00

0.0

1.0

—

Localized scleroderma [morphea]

0.00

-0.00

0.0

1.0

—

Use of interferon beta-1a

0.00

-0.00

0.0

1.0

—

Other and unspecified acute skin changes due to ultraviolet radiation

0.00

-0.00

0.0

1.0

—

Brain glioblastoma and astrocytoma

0.00

-0.00

0.0

1.0

—

Chronic crepitant synovitis/bursitis of hand and wrist/periarthritis of wrist

0.00

-0.00

0.0

1.0

—

0.00

-0.00

0.0

1.1

—

Complications associated with artificial fertilization

0.00

-0.00

0.0

1.0

—

Use of glatiramer acetate

0.00

-0.00

0.0

1.0

—

Disorders of synovium and tendon in diseases classified elsewhere

0.00

-0.00

0.0

1.0

—

Asthma mixed form (mode), excluding more controls

0.00

-0.00

0.0

1.0

—

Autism spe

0.00

-0.00

0.0

1.0

—

Drug-induced adrenocortical insufficiency

0.00

-0.00

0.0

1.0

—

Other disorders of thyroid

0.00

-0.00

0.0

1.0

—

Torsion of testis

0.00

-0.00

0.0

1.0

—

Inflammatory disorders of male genital organs, not elsewhere classified

0.00

-0.00

0.0

1.0

—

Habitual aborter

0.00

-0.00

0.0

1.0

—

Benign neoplasm: Short bones of upper limb

0.00

-0.00

0.0

1.0

—

Kyphosis

0.00

-0.00

0.0

1.0

—

HSIL lesion of the vagina

0.00

-0.00

0.0

1.0

—

Benign neoplasm: Connective and other soft tissue of lower limb, including hip

0.00

-0.00

0.0

1.0

—

Benign neoplasm: Other/unspecified site

0.00

-0.00

0.0

1.0

—

Benign neoplasm: Vulva

0.00

-0.00

0.0

1.0

—

Iron deficiency

0.00

-0.00

0.0

1.0

—

Bulimia nervosa (incl. atypical)

0.00

-0.00

0.0

1.0

—

Malignant neoplasm of vulva, including Hilmo

0.00

-0.00

0.0

1.0

—

Use of amantadine

0.00

-0.00

0.0

1.0

—

Autism

0.00

-0.00

0.0

1.0

—

Lagophthalmos

0.00

-0.00

0.0

1.0

—

Lack of expected normal physiological development

0.00

-0.00

0.0

1.2

—

Tuberculosis of other organs, strict

0.00

-0.00

0.0

1.0

—

≡ Risteys

R13

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Glomerular basement membrane Ab [Units/volume] in Serum

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS